Post Archive
AmyloSENS Therapies for Alzheimer’s: The Marathon and the Decathlon
The Phase III trials for AmyloSENS rejuvenation biotechnologies lecanemab/Leqembi® and donanemab showed that they are most effective when given to people with less of other kinds of cellular and molecular aging damage in their brains. New data illustrates that fact even more powerfully and gives us a foreshadowing of what’s possible if we make best use of these and forthcoming damage-repair longevity therapeutics.
Education Department February 2024 Updates
Read more about SRF Education programs highlights and upcoming events.
Education Department January 2024 Updates
Read more about SRF Education programs highlights and upcoming events.
Do the Hallmarks of Aging Make SENS? (Part Two)
A supporter asks if the Hallmarks of Aging could effectively be substituted for the seven categories of cellular and molecular damage in the SENS platform. The answer is ‘no,’ because the Hallmarks include both too much and too little, and most importantly because the Hallmarks fail to serve as a roadmap toward the biomedical postponement of aging.
Education Department December 2023 Updates
Read more about SRF Education programs highlights and upcoming events.
Do the Hallmarks of Aging Make SENS? (Part One)
A supporter asks if the Hallmarks of Aging could effectively be substituted for the seven categories of cellular and molecular damage in the SENS platform. The answer is ‘no,’ because the Hallmarks include both too much and too little, and most importantly because the Hallmarks fail to serve as a roadmap toward the biomedical postponement of aging.
Education Department November 2023 Updates
Read more about SRF Education programs highlights and upcoming events.
Education Department October 2023 Updates
Read more about SRF Education programs highlights and upcoming events.
Senolytics in Aging Muscle: Could the Cure Be Worse than the Disease?
Skeletal muscles are organized into long fibers, and when a fiber breaks the entire fiber is often lost. This made a supporter worry that senolytic therapies might break a muscle fiber and eliminate precious fibers in aging muscles. It appears that the injury at the heart of the questioner’s worry does not happen in practice.
More Studies on Metformin and Survival
In this update, we review two recent papers that address the question of people with type 2 diabetes who take metformin living longer than people without the disease who don’t, but without the flaw in the 2014 study. We find that, as expected, metformin is a good diabetes drug but shows no sign of being a longevity therapeutic.
Education Department September 2023 Updates
Read more about SRF Education programs highlights and upcoming events.
Sponsor a Student
SENS Research Foundation (SRF) is launching its campaign Sponsor a Student to increase charitable donations that will allow it to hire more student researchers and teach them that aging is not indisputable. Sponsoring a student dramatically transforms a young person’s life, giving them a chance to conduct world-class research and learn more about the career that awaits them.
Introducing the SRF-University of Toledo PhD Program
We are thrilled to announce the launch of a joint PhD program between SENS Research Foundation and the University of Toledo Biological Sciences Department. This program offers a unique opportunity for aspiring researchers to pursue their doctoral degree in the cutting-edge field of anti-aging research, with a damage-repair approach.
Education Department August 2023 Updates
Read more about SRF Education programs highlights and upcoming events.
Set My Heart Free: Two AmyloSENS Therapies Targeting Cardiac Amyloid in Clinical Trials
TTR cardiac amyloid contributes to heart failure and appears to limit the lives of the longest-lived humans. One AmyloSENS antibody shows high promise to remove this amyloid and restore function in the aging heart in an early-stage clinical trial. A second such antibody is coming close behind it, and a tiny number of people’s immune systems appear to generate such antibodies on their own.
The Grand Opening of Our New Facilities
June 23, 2023 – SRF had the Grand Opening of our expanded Research Center in Mountain View, CA. In attendance were local and state dignitaries, members of the SRF Board, SRF senior staff and scientific leads, SRF staff and Education program participants, and a number of distinguished and welcome guests.
Education Department July 2023 Updates
The 2023 application season is coming to a close with a very competitive applicant pool. Read more about highlights and upcoming events.
From Parachutes to Jetpacks: Clearing Brain Beta-Amyloid with Donanemab or Lecanemab Works, Though More Must be Done
Another clinical trial has now proven that a second AmyloSENS rejuvenation biotechnology that clears beta-amyloid aggregates from the brain also slows down the slide into dementia in people in the early stages of Alzheimer’s disease, but this development is only the beginning.
